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Abstract
Background: In metastatic breast cancer, the status of the estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2), as well as the Ki-67 index sometimes change between primary
and metastatic lesions. However, the change in expression levels of enhancer of zeste homolog 2 (EZH2) between
primary and metastatic lesions has not been determined in metastatic breast cancer.
Methods: Ninety-six metastatic breast cancer patients had biopsies or resections of metastatic lesions between
September 1990 and February 2014 at the Kanagawa Cancer Center. We evaluated ER, PR, HER2, Ki-67, and EZH2 in
primary lesions and their corresponding metastatic lesions using immunohistochemistry. We examined the change
in expression of EZH2 between primary and metastatic lesions, the correlation between the expression of EZH2 and
the expression of other biomarkers, and the relationship between EZH2 expression and patient outcome in
metastatic breast cancer.
Results: EZH2 expression was significantly higher in metastatic lesions compared with primary lesions. EZH2 expression
was highly correlated with Ki-67 expression in primary and metastatic lesions. High-level expression of EZH2
was associated with poorer disease-free survival (DFS) outcomes in patients with primary lesions (P < 0.001);
however, high-level expression of EZH2 was not associated with poorer DFS outcomes in patients with metastatic
lesions (P = 0.063). High-level expression of EZH2 was associated with poorer overall survival (OS) postoperatively in
patients with primary (P = 0.001) or metastatic lesions (P = 0.005). High-level expression of EZH2 was associated with
poorer OS outcomes after recurrence in patients with metastatic lesions (P = 0.014); however, high-level expression of
EZH2 was not associated with poorer OS outcomes after recurrence in patients with primary lesions (P = 0.096).
High-level expression of EZH2 in metastatic lesions was independently associated with poorer OS outcomes after recurrence.
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Conclusions: EZH2 expression was significantly increased in metastatic lesions compared with primary lesions. High-level
expression of EZH2 in metastatic lesions was associated with poorer OS outcomes after primary surgery and recurrence.
Keywords: Metastatic breast cancer, EZH2, Ki-67, Prognostic factor, Immunohistochemistry, Epigenetics
Background
Metastatic breast cancer (MBC) is difficult to treat using
currently available conventional therapies, and median
long-term survival rates in MBC patients have been
reported to be as little as 18–24 months or 2–4 years
from the time of diagnosis [1, 2]. Following chemotherapy,
10-year survival rates are approximately 5% and 2–3% in
patients with MBC and those who survive >20 years,
respectively [3, 4].
Management of MBC generally consists of systemic treat-
ment (chemotherapy and targeted therapy, including anti-
estrogen and anti-human epidermal growth factor receptor
2 [HER2] therapies). Treatment decisions for patients with
MBC are usually based on estrogen receptor (ER), proges-
terone receptor (PR) and HER2 status of the primary
tumor, the disease-free interval (DFI), site(s) of recurrence
and performance status [5]. Because performing biopsies of
metastatic lesions risks damaging vital organs and tissues,
investigation of biomarkers in metastatic lesions is often
challenging. Therefore, based on biomarkers in the primary
tumor, the systemic treatment is often given to MBC pa-
tients. However, previously published reports show that,
because biomarker levels change between primary and
metastatic lesions, surgical biopsy of metastatic lesions
followed by pathological confirmation for the investigation
of biomarkers is occasionally proposed as an effective
strategy in the treatment of MBC patients [6–12].
Enhancer of zeste homolog 2 (EZH2) is a well-known
histone modifier protein that functions as a methyltrans-
ferase at lysine 27 of histone H3 [13]. EZH2 is a member
of the polycomb group of genes [14] that is important
for transcriptional regulation through chromatin remod-
eling, nucleosome modification and interactions with
other transcription factors. It is assumed that EZH2
promotes breast cancer progression by transcriptional
repression of tumor suppressors and by maintaining
cells in a stem cell-like state [15, 16]. EZH2 has been
demonstrated to be overexpressed in many types of
malignancies, including breast, prostate and endometrial
cancers, and has been suggested as a candidate for
targeted treatment [17, 18]. In primary breast cancer
(PBC), Kleer et al. [17] showed that EZH2 overexpres-
sion was further associated with a larger tumor size, ER-
and PR-negative status, an advanced stage of disease,
and significantly reduced disease-free survival (DFS) and
overall survival (OS). Other investigators have reported
that EZH2 promotes neoplastic progression in the
breast, and that downregulation in EZH2 expression
reduces in vivo tumor growth of breast cancer cells
[17, 19, 20]. EZH2 is important for the control of cell
proliferation and invasion, and has recently been
shown to regulate DNA repair pathways and genomic
stability [19, 21–24]. However, few reports have ex-
amined EZH2 expression in metastatic lesions,
changes in EZH2 expression levels between primary
and metastatic lesions, and patient outcome measures
in MBC in relation to EZH2 expression.
The purpose of this study was to examine the ex-
pression levels of EZH2 in 96 pairs of primary cancer
tissues and metastatic lesions obtained from patients
with MBC. To evaluate the clinicopathological signifi-
cance of EZH2 expression in metastatic lesions, we
examined the correlations and changes in ER, PR,
HER2, Ki-67 and EZH2 expression between primary
cancer tissues and metastatic lesions, and DFS and
OS outcomes after primary surgery and recurrence in
patients with MBC.
Methods
Patients and samples
We retrospectively studied surgical specimens of PBC
tumors and their corresponding metastatic lesions from
patients who underwent surgery for their PBC tumor at
the Kanagawa Cancer Center, Yokohama, Japan, between
December 1977 and March 2013. Of those who relapsed
after primary surgery between September 1990 and
February 2014, there were 96 consecutive patients from
whom metastatic lesions were obtained, either by surgery
or biopsy, and evaluated using immunohistochemistry
(IHC). In all cases, archival hematoxylin and eosin-stained
slides of the PBC tumor and its corresponding metastatic
lesion were retrieved and reviewed for confirmation of
pathological features, as well as to select suitable tissue
blocks for IHC analysis. We constructed tissue microar-
rays (TMAs) using PBC tumors and metastatic lesions. In
patients receiving neoadjuvant chemotherapy, we exam-
ined the PBC tumor using a core needle biopsy before
treatment was commenced in order to avoid potential
bias. The Ethics Committees of the Kanagawa Cancer
Center, Yokohama, Japan, approved the study protocol.
TMAs
TMAs consisting of cores, each measuring 2 mm in
diameter, were assembled from formalin-fixed, paraffin-
Inari et al. BMC Cancer  (2017) 17:160 Page 2 of 14
embedded blocks of surgically removed tissue from pri-
mary tumors and their metastatic lesions in breast can-
cer patients. We included tissue cores from each
primary tumor, metastatic lesion and normal breast tis-
sue, which was used as a control, in the array.
IHC analysis
IHC staining for biomarkers ER, PR, HER2, Ki-67 and
EZH2 was performed in all cases. TMAs were cut into 4-
μm-thick sections and mounted onto pre-coated glass
slides. All sections were stained using an autostainer
(trade name Histostainer; Nichirei Biosciences Inc., Tokyo,
Japan) using primary antibodies to ER (clone 1D5, dilution
1:80; Nichirei Biosciences Inc., Tokyo, Japan), PR (clone
A9621A, dilution 1:100; Nichirei Biosciences Inc., Tokyo,
Japan), HER2 (clone D8F12, dilution 1:800; Cell Signaling
Technology Inc., Danvers, MA, USA), Ki-67 (clone SP-6,
dilution 1:200; Nichirei Biosciences Inc., Tokyo, Japan)
and EZH2 (clone D2C9, dilution 1:50; Cell Signaling
Technology Inc., Danvers, MA, USA).
The results of the IHC analysis were assessed in a
blinded fashion by a breast surgeon (H.I.) and patholo-
gist (K.K.) who examined each slide independently. Un-
clear cases were discussed between the breast surgeon
and pathologist. Each tumor was assessed twice and an
average was calculated between the two scores. Nuclear
immunoreactivity of each hormone receptor was scored
independently by evaluating the percentage of positively
stained cancer cells. ER and PR were defined as positive
if there was staining of ≥1% of tumor cell nuclei. HER2
expression was scored as 0, 1+, 2+ or 3+ in accordance
with the guidelines of the American Society of Clinical
Oncology/College of American Pathologists [25]. A
HER2 score of 3+ was considered positive. IHC 2+
tumors were not analyzed using in situ hybridization
techniques. A HER2 score of 2+ was considered negative
(see Additional file 1).
Regardless of the staining intensity, nuclear immuno-
reactivity of EZH2 and Ki-67 expression were scored in-
dependently by evaluating the proportion of positively
stained cancer cells: Score 1 = ≤1/100 cells stained; Score
2 = ≤1/10 cells stained; Score 3 = ≤1/3 cells stained;
Score 4 = ≤2/3 cells stained; and Score 5 > 2/3 cells
stained (Fig. 1). EZH2 expression scores of 4 and 5, and
Ki-67 expression scores of 3, 4 and 5, were considered
high expression. EZH2 expression scores of 1, 2 and 3,
and Ki-67 expression scores of 1 and 2 were considered
low expression. The median EZH2 score and Ki-67
expression score across all PBC tumors sampled were 4
and 3, respectively (see Additional file 2).
ER, PR, HER2 and Ki-67 expression were used to identify
distinct molecular subtypes (Table 1). These were defined
as follows: luminal A = ER and/or PR+, HER2−, and low
Ki-67 expression; luminal B = ER and/or PR+, HER2−, and
high Ki-67 expression; luminal HER2 = ER and/or PR+,
HER2+; HER2-type = ER and PR−, HER2+; and triple-
negative breast cancer (TNBC) = ER and PR−, HER2 − .
Follow-up
Follow-up was performed using the KCCH Cancer
Registry until October 31, 2015. Active follow-up was
conducted by accessing hospital visit records, resident
registration cards, and permanent domicile data. Dur-
ing the study period, no subject was lost to follow-up.
The day of the biopsy of the metastatic lesions was
defined as the date of diagnosis of recurrence. DFS
was defined as the period from the day of primary
surgery until the day of the biopsy of the metastatic
lesions. OS after primary surgery was defined as the
period from the day of primary surgery until the day
of death. OS after recurrence was defined as the
period from the day of biopsy of the metastatic
lesions until the day of death. Median follow-up time
was 96 months (range, 1–299 months) after the pri-
mary operation, and median follow-up time was
40 months (range, 0–231) after recurrence.
Statistical analyses
Relationships between biomarkers of the primary and
metastatic breast cancer lesions and clinicopathological
characteristics of the patients were analyzed using chi-
square tests. Correlations between EZH2 expression and
that of other biomarkers were evaluated using Pearson
product-moment correlation coefficients (r). EZH2 and
Ki-67 scores between primary and metastatic breast
cancer lesions were compared using independent t-tests.
DFS, survival rates after primary surgery, and survival
rates after recurrence were analyzed using the Kaplan–
Meier method, and any differences in survival rates were
assessed using log-rank tests according to the expression
of EZH2 in the primary and metastatic lesions. Cox pro-
portional hazards models were applied to the multivari-
ate analyses. Since we showed Ki-67 expression and
EZH2 expression in primary and metastatic lesions to be
strongly correlated (Table 2), we assessed prognostic
factors (except for the Ki-67 expression) in multivariate
analysis. For Pearson product-moment correlation
coefficients (r), a P < 0.01, and for chi-square tests, inde-
pendent t-tests, log-rank tests and Cox proportional-
hazards models, a P < 0.05 was considered statistically
significant. All statistical analyses were performed using
SPSS version 20 (SPSS Inc., Chicago, IL, USA).
Results
Clinicopathological characteristics of all patients with
MBC in this study
Patient characteristics are summarized in Table 3. Among
96 biopsies or resections of metastases, 26 (27.0%) were of
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brain, eight (8.3%) of lung, one (1.0%) of liver, two
(2.0%) of ovary, 13 (13.5%) of chest wall, 15 (15.6%)
of lymph nodes, seven (7.3) of distant skin and 24
(25%) of bone.
Changes in ER, PR, HER2, Ki-67 and EZH2 expression
between primary and metastatic lesions
Compared with primary lesions, metastatic lesions
exhibited significantly higher levels of expression of
Ki-67 (75.0% vs. 57.3% P = 0.010) and EZH2 (82.3% vs.
56.3% P < 0.0001). Conversely, no statistical differences
in ER (42.7% vs. 53.1%, P = 0.149), PR (40.6% vs. 49.0%,
P = 0.246) or HER2 status (14.6% vs. 16.7%, P = 0.691)
were observed between primary and metastatic lesions
(Table 1). We subsequently analyzed the scores of
expression levels of Ki-67 and EZH2, which demon-
strated a significant difference between the two
groups (i.e., high vs. low expression) (Fig. 2). The means
and standard deviations of the Ki-67 scores were 2.74
± 0.92 and 3.10 ± 0.97 for primary and metastatic
lesions, respectively (P = 0.009) (Fig. 2a), while the
means and standard deviations of the EZH2 expres-
sion scores were 3.56 ± 1.34 and 4.26 ± 1.08 for pri-
mary and metastatic lesions, respectively (P < 0.001)
(Fig. 2b). Ki-67 and EZH2 expression scores were sig-
nificantly higher in metastatic lesions compared with
PBC lesions.
Correlation coefficients of ER, PR, HER2, Ki-67 and EZH2
expression scores in primary and metastatic lesions
In PBC lesions, ER (r=−0.103, P= 0.318) and PR (r=−0.111,
P= 0.282) status were not significantly correlated with
EZH2 expression, HER2 status exhibited a significant
low correlation with EZH2 expression (r = 0.361, P <
0.001), and Ki-67 expression exhibited a significant high
correlation with EZH2 expression (r = 0.722, P <
0.0001) (Table 2). Similarly, in metastatic lesions, ER
(r = −0.099, P = 0.339) and PR (r = −0.190, P = 0.064)
status were not significantly correlated with EZH2 expres-
sion, HER2 status exhibited a significant low correlation
Fig. 1 Representative breast tissue sections stained with an antibody to EZH2. Representative examples of primary tissue or metastatic tissue cores
presenting with five levels of staining for enhancer of zeste homolog 2 (EZH2):a normal breast; b ≤1/100 cells stained (Score 1); c ≤1/10 cells stained
(Score 2); d ≤1/3 cells stained (Score 3); e ≤2/3 cells stained (Score 4); and f >2/3 stained (Score 5) (Original magnification, 200× The under bar is 200 μm.)
Inari et al. BMC Cancer  (2017) 17:160 Page 4 of 14
Table 1 Comparison of estrogen receptor, progesterone
receptor, human epidermal growth factor receptor 2, Ki-67, and
enhancer of zeste homolog 2 biomarkers between primary lesions
and metastatic lesions in breast cancer patients (n = 96)
Biomarker Primary lesions Metastatic lesions P-value
ER status, n (%)
positive 51 (53.1) 41 (42.7) 0.149
negative 45 (46.9) 55 (57.3)
PR status, n (%)
positive 47 (49.0) 39 (40.6) 0.246
negative 49 (51.0) 57 (59.4)
HER2 status, n (%)
positive 16 (16.7) 14 (14.6) 0.691
negative 80 (83.3) 82 (85.4)
Ki-67 expression, n (%)
high 55 (57.3) 72 (75.0) 0.010*
low 41 (42.7) 24 (25.0)
EZH2 expression, n (%)
high 54 (56.3) 79 (82.3) <0.0001*
low 42 (43.7) 17 (17.7)
Molecular subtype, n (%)
luminal Aa 31 (32.3) 19 (19.8) 0.304
luminal Bb 22 (22.9) 29 (30.2)
luminal HER2c 5 (5.2) 5 (5.2)
HER2-typed 11 (11.5) 9 (9.4)
TNBCe 27 (28.1) 34 (35.4)
Abbreviations: ER estrogen receptor, EZH2 enhancer of zeste homolog 2, HER2
human epidermal growth factor receptor 2, PR progesterone receptor, TNBC
triple-negative breast cancer
aLuminal A = ER and/or PR+, HER2−, and low Ki-67 expression
bLuminal B = ER and/or PR+, HER2−, and high Ki-67 expression
cLuminal HER2 = ER and/or PR+, HER2+
dHER2-type = ER and PR−, HER2+
eTNBC = ER and PR−, HER2−
*Indicates values that are statistically significant (P < 0.05)
Table 2 Correlation coefficient of biomarkers and EZH2 scores
EZH2 r P-value
Primary ER status Primary −0.103 0.318
Primary PR status Primary −0.111 0.282
Primary HER2 status Primary 0.361 <0.001*
Primary Ki-67 expression Primary 0.722 <0.0001*
Metastatic ER status Metastatic −0.099 0.339
Metastatic PR status Metastatic −0.190 0.064
Metastatic HER2 status Metastatic 0.306 0.002*
Metastatic Ki-67 expression Metastatic 0.685 <0.0001*
Abbreviations: ER estrogen receptor, EZH2 enhancer of zeste homolog 2, HER2
human epidermal growth factor receptor 2, PR progesterone receptor
*Indicates values that are statistically significant (P < 0.01)
Table 3 Clinicopathological Characteristics of all metastatic
patients in this study
Characteristic Patients (n = 96) Percent
Age, years (mean ± SD) 51 ± 7.5
Menopausal status
pre- 44 45.8
post- 52 54.2
Tumor size
≤ 20 mm 17 17.7
> 20 mm 77 80.2
unknown 2 2.1
LN status
positive 63 65.6
negative 33 34.4
Histological type
ductal 83 86.5
speciala 13 13.5
LVI status
positive 63 65.6
negative 25 26.1
unknown 8 8.3
Operation status
partial mastectomy 17 17.8
mastectomy 79 82.2
Stage at the primary diagnosis
1 11 11.5
2 48 50
3 34 35.4
4 1 1.0
unknown 2 2.0
Chemotherapy
adjuvant 83 86.5
none 13 13.5
Hormone therapy
adjuvant 50 52.1
none 46 47.9
Site of recurrence
brain 26 27.0
lung 8 8.3
liver 1 1.0
ovary 2 2.1
chest wall 13 13.5
lymph node 15 15.6
distant skin 7 7.3
bone 24 25
Abbreviations: LN lymph node, LVI lymphovascular invasion, SD standard deviation
aSpecial type is invasive breast carcinoma except invasive ductal carcinoma
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with EZH2 expression (r = 0.306, P = 0.002), and Ki-67 ex-
pression scores exhibited a high correlation with EZH2
expression (r = 0.685, P < 0.001) (Table 2).
Relationship between EZH2 expression and patient
clinicopathological characteristics
Patient clinicopathological characteristics and their cor-
relation with EZH2 expression in primary and metastatic
lesions are summarized in Table 4. Relationships
between the expression level status of EZH2 and patient
age, menopausal status, tumor size, lymph node status,
histological type (i.e., ductal vs. special), lymphovascular
invasion status, operation status (i.e., partial vs. full
mastectomy), adjuvant chemotherapy and hormone
therapy status, primary ER status, primary PR status, pri-
mary HER2 status, primary Ki-67 expression, metastatic
ER status, metastatic PR status, metastatic HER2 status,
metastatic Ki-67 expression, the site(s) of recurrence
(i.e., viscera, soft tissue or bone) and DFI (disease-free
interval) (i.e., ≤2 years, >2 years, ≤10 years, >10 years)
were evaluated. Factors significantly associated with PBC
lesions included lymph node status, histological type,
primary ER status, metastatic PR status, primary and
metastatic HER2 status, primary and metastatic Ki-67
expression, and DFI, whereas factors significantly associ-
ated with metastatic lesions included histological type,
adjuvant chemotherapy status, primary PR status,
primary HER2 status, primary and metastatic Ki-67
expression, and the site(s) of recurrence (Table 4).
Relationship between EZH2 expression and patient
outcome
We examined DFS and OS outcomes after primary
surgery and recurrence in patients with MBC according
to primary EZH2 expression (Fig. 3a, b, c), and DFS and
OS outcomes after primary surgery and recurrence in
patients with MBC according to metastatic EZH2
expression (Fig. 3d, c, f ). Patient clinicopathological
characteristics and their correlation with EZH2 expres-
sion in primary and metastatic lesions are summarized
in Table 4. First, DFS, survival rates after primary sur-
gery, and survival rates after recurrence were analyzed
according to the expression of EZH2 in PBC lesions.
Low EZH2 expression in PBC lesions occurred in 42
patients and high EZH2 expression in PBC lesions in 54
patients. Median DFS time in patients with high expres-
sion levels of EZH2 in PBC lesions was 30 compared
with 74 months in patients with low expression levels of
EZH2 in PBC lesions (Fig. 3a). Median survival time
after primary surgery in patients with high expression
levels of EZH2 in PBC lesions was 55 compared with
133 months in patients with low expression levels of
EZH2 in PBC lesions (Fig. 3b). Patients expressing high
levels of EZH2 in PBC lesions had significantly poorer
DFS and OS outcomes than patients expressing low
levels of EZH2 in PBC lesions (P < 0.001, P = 0.001).
Second, DFS, survival rates after primary surgery, and
survival rates after recurrence were analyzed according
to the expression of EZH2 in the metastatic lesions. Low
EZH2 expression in metastatic lesions occurred in 17
patients and high EZH2 expression in metastatic lesions
occurred in 79 patients. Median survival time after
primary surgery in patients with high expression levels
of EZH2 in metastatic lesions was 66 compared with
161 months in patients with low expression levels of
EZH2 in metastatic lesions (Fig. 3e). Median survival
time after recurrence in patients with high expression
levels of EZH2 in metastatic lesions was 25 compared
with 50 months in patients with low expression levels of
EZH2 in metastatic lesions (Fig. 3f ). Patients expressing
high levels of EZH2 in metastatic lesions had signifi-
cantly poorer OS outcomes after primary surgery and
recurrence than patients expressing low levels of EZH2
in metastatic lesions (P = 0.005, P = 0.014).
a b
Fig. 2 Comparison of the Ki67 expression score and EZH2 expression between primary and metastatic lesions. The mean and standard deviation
score of (a) Ki67 expression in primary lesions was 2.74 ± 0.92, and in metastatic lesions was 3.10 ± 0.97. The mean and standard deviation score
of (b) EZH2 expression in primary lesions was 3.56 ± 1.34, and in metastatic lesions was 4.26 ± 1.08
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Table 4 Relationship betweenEZH2 expression in primary and metastatic breast cancer lesions and the clinicopathological
characteristics of patients (n = 96)
Characteristic Primary EZH2 P-value Metastatic EZH2 P-value
low (n = 42) high (n = 54) low (n = 17) high (n = 79)
Age, years (mean ± SD) 52 ± 8.5 50 ± 9.8 0.198 50 ± 7.8 51 ± 9.7 0.241
Menopausal status, n (%)
pre- 17 (38.6) 27 (61.4) 0.353 10 (22.7) 34 (77.3) 0.236
post- 25 (48.1) 27 (51.9) 7 (13.5) 45 (86.5)
Tumor size, n (%)
≤ 20 mm 8 (47.1) 9 (52.9) 2 (11.8) 15 (88.2)
> 20 mm 33 (42.9) 44 (57.1) 0.936 14 (18.2) 63 (81.8) 0.396
unknown 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0)
LN status, n (%)
positive 23 (36.5) 40 (63.5) 11 (17.5) 52 (82.5)
negative 19 (57.6) 14 (42.4) 0.048* 6 (18.2) 27 (81.8) 0.930
Histological type, n (%)
ductal 32 (38.6) 51 (61.4) 0.010* 12 (14.5) 71 (85.5) 0.035*
special 10 (76.9) 3 (23.1) 5 (38.5) 8 (61.5)
LVI status, n (%)
positive 32 (50.8) 31 (49.2) 11 (17.5) 52 (82.5)
negative 8 (32.0) 17 (68.0) 0.148 4 (16.0) 21 (84.0) 0.842
unknown 2 (25.0) 6 (75.0) 2 (25.0) 6 (75.0)
Operation status, n (%)
partial mastectomy 4 (23.5) 13 (76.5) 0.064 2 (11.8) 15 (88.2) 0.479
mastectomy 38 (48.1) 41 (51.9) 15 (19.0) 64 (81.0)
Chemotherapy, n (%)
adjuvant 34 (41.0) 49 (59.0) 0.164 12 (14.5) 71 (85.5) 0.035*
none 8 (61.5) 5 (38.5) 5 (38.5) 8 (61.5)
Hormone therapy, n (%)
adjuvant 26 (52.0) 24 (48.0) 0.089 12 (24.0) 38 (76.0) 0.092
none 16 (34.8) 30 (65.2) 5 (10.9) 41 (89.1)
Primary ER status, n (%)
positive 28 23 0.019* 12 39 0.112
negative 14 31 5 40
Primary PR status, n (%)
positive 24 23 0.157 12 35 0.049*
negative 18 31 5 44
Primary HER2 status, n (%)
positive 1 15 0.001* 0 16 0.042*
negative 41 39 17 63
Primary Ki-67 expression, n (%)
high 8 47 <0.001* 2 53 <0.001*
low 34 7 15 26
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In the univariate analysis, compared with low EZH2
expression, high EZH2 expression was not a poor prog-
nostic indicator of OS after recurrence outcome in PBC
(hazard ratio [HR] 1.449; 95% confidence interval [CI]
0.930–2.258, P = 0.101) (Table 5), whereas in metastatic
lesions, high EZH2 expression was a poor prognostic
indicator of OS outcome after recurrence (HR 2.116;
95% CI 1.143–3.916, P = 0.017) (Table 5). Other poor
prognostic indicators of OS outcome after recurrence in
PBC and metastatic lesions from the univariate analysis
included primary ER or primary PR status, primary and
metastatic high Ki-67 expression, and ≤2 years of DFI
(Table 5). A Cox proportional-hazards model using
multivariate analysis but not including Ki-67 expression
demonstrated that high EZH2 expression was independ-
ently associated with poorer OS outcomes after recur-
rence in patients with metastatic lesions (HR 2.047; 95%
CI 1.074–3.902, P = 0.029) (Table 5). Multivariate
analysis of prognostic factors related to OS after recur-
rence including Ki-67 expression is shown in Additional
file 3: Table S1.
Discussion
In this study, using primary and paired metastatic
lesions from patients with MBC, EZH2 expression
scores correlated significantly with Ki-67 expression
scores in both primary and metastatic lesions, and Ki-67
expression and EZH2 expression scores were signifi-
cantly higher in metastatic lesions compared with PBC
lesions. Because Ki-67 expression scores in metastatic
lesions increased more than in PBC lesions, we consid-
ered that proliferation in metastatic lesions increased
more than in PBC lesions. We expected that EZH2 ex-
pression in metastatic lesions would be higher than that
in PBC lesions. We showed that EZH2 expression corre-
lated significantly with the Ki-67 expression in both PBC
and metastatic lesions. We thought that EZH2 promotes
breast cancer progression by transcriptional repression
of tumor suppressors; consequently, Ki-67 expression
increased in breast cancer cells with high EZH2 expres-
sion. We showed that EZH2 expression levels in bone
metastatic lesions were significantly lower than in
viscera and soft tissue metastatic lesions. Expression of
Table 4 Relationship betweenEZH2 expression in primary and metastatic breast cancer lesions and the clinicopathological
characteristics of patients (n = 96) (Continued)
Metastatic ER status, n (%)
positive 21 20 0.203 8 33 0.689
negative 21 34 9 46
Metastatic PR status, n (%)
positive 22 17 0.039* 9 30 0.254
negative 20 37 8 49
Metastatic HER2 status, n (%)
positive 1 13 0.003* 0 14 0.060
negative 41 41 17 65
Metastatic Ki-67 expression, n (%)
high 23 49 <0.001* 2 70 <0.001*
low 19 5 15 9
Site of recurrence, n (%)
viscerab 14 (37.8) 23 (62.2) 0.102 5 (13.5) 32 (86.5) 0.012*
soft tissuec 13 (37.1) 22 (62.9) 3 (8.6) 32 (91.4)
bone 15 (62.5) 9 (37.5) 9 (37.5) 15 (62.5)
Disease free interval
≤ 2 years 7 (23.5) 24(77.4) 0.04* 4 (12.9) 27 (87.1) 0.394
> 2 years 35 (53.8) 30 (46.1) 13 (20) 52 (80)
≤ 10 years 32 (38.6) 51 (61.4) 0.010* 13 (15.7) 70 (84.3) 0.185
> 10 years 10 (76.9) 3 (23.1) 4 (30.8) 9 (69.2)
Abbreviations: ER estrogen receptor, EZH2 enhancer of zeste homolog 2, HER2 human epidermal growth factor receptor 2, LN lymph node, LVI lymphovascular
invasion, PR progesterone receptor, SD standard deviation
aSpecial type is invasive breast carcinoma except invasive ductal carcinoma
bViscera includes brain, lung, liver and ovary
cSoft tissues includes chest wall, lymph node, distant skin
*Indicates values that are statistically significant (P < 0.05)
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EZH2 in primary tumors of patients with DFIs ≤2 years
was higher than in those with DFIs >2 years, whereas ex-
pression of EZH2 in primary tumors of patients with
DFIs >10 years was lower than in those with DFIs
≤10 years. Given that bone metastasis occurs more fre-
quently in ER-positive than ER-negative breast cancer
[26] and in MBC patients with DFIs >10 years [27], we
expected that EZH2 expression would be low in bone
a b
c d
e f
Fig. 3 Kaplan–Meier survival curves for breast cancer patients (n = 96) with high and low enhancer of zeste homolog 2 (EZH2) expression.
Kaplan–Meier survival curves for breast cancer patients with high and low enhancer of zeste homolog 2 (EZH2) expression in (a) disease-free survival in
patients with primary lesions, b overall survival in patients after primary surgery with primary lesions, c overall survival in patients after recurrence with
primary lesions, d disease-free survival in patients with metastatic lesions, e overall survival in patients after primary surgery with metastatic lesions, and
(f) overall survival in patients after recurrence with metastatic lesions
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Table 5 Univariate and multivariate analysis of prognostic factors related to overall survival after recurrence (n = 96)
Prognostic factor Patients
(n = 96)
Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Menopausal status, n (%)
pre- 44 (45.8) 1
post- 52 (54.2) 1.396 0.891–2.186 0.145
Tumor size, n (%)
≤ 20 mm 17 (17.7) 1
> 20 mm 77 (80.2) 1.317 0.726–2.388 0.364
unknown 2 (2.1)
LN status, n (%)
positive 63 (65.6) 1.309 0.829–2.066 0.248
negative 33 (34.4) 1
Histological type, n (%)
ductal 83 (86.5) 1
speciala 13 (13.5) 1.028 0.543–1.945 0.932
LVI status, n (%)
positive 63 (65.6) 1.287 0.769–2.156 0.337
negative 25 (26.1) 1
unknown 8 (8.3)
Operation status, n (%)
partial mastectomy 17 (17.7) 1
mastectomy 79 (82.3) 0.894 0.500–1.596 0.704
Chemotherapy, n (%)
adjuvant 83 (86.5) 1.320 0.707–2.461 0.383
none 13 (13.5) 1
Hormone therapy, n (%)
adjuvant 50 (52.1) 0.719 0.460–1.122 0.146
none 46 (47.9) 1
Primary ER status, n (%)
positive 51 (53.1) 0.541 0.344–0.850 0.008* 0.724 0.382–1.372 0.322
negative 45 (46.9) 1
Primary PR status, n (%)
positive 47 (49.0) 0.595 0.380–0.931 0.023* 0.911 0.484–1.714 0.773
negative 49 (51.0) 1
Primary HER2 status, n (%)
positive 16 (16.7) 1.122 0.616–2.046 0.706
negative 80 (83.3) 1
Primary Ki-67 expression, n (%)b
high 55 (57.3) 1.848 1.170–2.917 0.008*
low 41 (42.7) 1
Primary EZH2 expression, n (%)
high 54 (56.3) 1.449 0.930–2.258 0.101
low 42 (43.7) 1
Inari et al. BMC Cancer  (2017) 17:160 Page 10 of 14
metastasis and in MBC patients with DFIs >10 years.
However, because MBC patients with DFIs ≤2 years had
a poor prognosis, we expected that EZH2 expression
levels would be higher. We showed that high EZH2
expression in primary lesions was shown to be inde-
pendently associated with poorer DFS and OS outcomes
after primary surgery in MBC, whether or not high
EZH2 expression in primary lesions was shown to be
associated with OS after recurrence. High EZH2 expres-
sion in metastatic lesions was not associated with DFS
after primary surgery, even if high EZH2 expression in
metastatic lesions was shown to be independently asso-
ciated with poorer OS outcomes after primary surgery
and recurrence. We had considered the proliferation of
primary lesions associated with DFS and OS after
primary surgery until recurrence; on the other hand,
proliferation of metastatic lesions was more associated
with OS after recurrence than PBC lesions.
Previous reports have demonstrated that in PBC,
EZH2 expression was significantly increased in malig-
nant tumors, and was associated with a larger tumor
size, ER- and PR-negative status, TNBC, advanced stage
disease and reduced progression-free survival and OS
[17, 28, 29]. In colon cancer and poorly differentiated
synovial sarcomas, EZH2 expression was significantly
related to increased tumor cell proliferation, as assessed
using the Ki-67 expression [30, 31]. Nishimura et al. [12]
reported that, in comparison to primary lesions, the
Ki-67 expression score increased significantly in meta-
static lesions. We found that in breast cancer patients,
EZH2 expression scores correlated significantly with
Ki-67 expression scores in both primary and metastatic
lesions and Ki-67 expression and EZH2 expression
scores were significantly higher in metastatic lesions
compared with PBC lesions. Furthermore, high EZH2
expression in metastatic lesions was shown to be inde-
pendently associated with poorer OS outcomes after
recurrence in MBC. Few reports have examined the
relationship between EZH2 expression in metastatic
lesions and outcomes in patients with MBC.
MBC is difficult to treat using conventional therapies that
are currently available on the market, and development of
Table 5 Univariate and multivariate analysis of prognostic factors related to overall survival after recurrence (n = 96) (Continued)
Metastatic ER status, n (%)
positive 41 (42.7) 0.972 0.625–1.513 0.901
negative 55 (57.3) 1
Metastatic PR status, n (%)
positive 39 (40.6) 0.692 0.440–1.089 0.112
negative 57 (59.4) 1
Metastatic HER2 status, n (%)
positive 14 (14.6) 1.282 0.673–2.440 0.450
negative 82 (85.4) 1
Metastatic Ki-67 expression, n (%)b
high 72 (75.0) 2.422 1.394–4.206 0.002*
low 24 (25.0) 1
Metastatic EZH2 expression, n (%)
high 59 (77.6) 2.116 1.143–3.916 0.017* 2.047 1.074–3.902 0.029*
low 17 (22.4) 1
Metastatic sites, n (%)
bones 24 (25.0) 0.899 0.548–1.476 0.674
others 72 (75.0) 1
Disease free interval
≤ 2 years 28 (29.0) 1.713 1.086–2.702 0.021* 1.601 0.978–2.621 0.061
> 2 years 68 (71.0) 1
≤ 10 years 83 (87.0) 1
> 10 years 13 (13.0) 0.861 0.442–1.679 0.661
Abbreviations: CI confidence interval, ER estrogen receptor, EZH2 enhancer of zeste homolog 2, HER2 human epidermal growth factor receptor 2, HR hazard ratio,
LN lymph node, LVI lymphovascular invasion, PR progesterone receptor
aSpecial type is invasive breast carcinoma except invasive ductal carcinoma
bKi-67 expression was excluded from the multivariate analysis because of an association with EZH2 expression in primary and metastatic breast cancer lesions
*Indicates values that are statistically significant (P < 0.05)
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new therapeutic approaches is needed. Considering the
downstream effects of EZH2, silencing of the EZH2 gene in
the ER+ MCF-7 cell line resulted in higher expression of
ER and increased sensitivity to anti-estrogen therapy [32].
EZH2 gene silencing has also been reported to result in a
significant reduction in tumor growth in the MB-231
TNBC orthotopic mouse model of breast carcinomas. High
EZH2 expression was shown to be significantly associated
with TNBC and reduced OS outcomes [28]. In our cohort
of MBC patients, we demonstrated a significant correlation
between EZH2 expression and Ki-67 expression scores in
primary and metastatic lesions. Therefore, EZH2 may
represent a potential therapeutic target for this aggressive
breast cancer that exhibits high expression levels of Ki-67,
thus warranting further investigation. Using data obtained
in this study as a reference of expression of EZH2 status in
metastatic lesions and the correlation between EZH2 and
other biomarkers in MBC, biopsy of metastatic lesions may
become less necessary, thereby avoiding risk of vital organ
damage because of the biopsy procedure.
Recently, several EZH2 inhibitors have been developed
and tested in multiple types of cell lines and xenografts
[33, 34]. Both EPZ-6438 (E7438) and GSK126, selective
small-molecule inhibitors of histone methyltransferase
activity, have yielded promising results in small cell
lung cancer cell lines and malignant rhabdoid tumors
[33, 34]. In the second quarter of 2015, Epizyme®
Inc., Cambridge, MA, USA initiated a phase 2 mono-
therapy trial of EPZ-6438 in patients with relapsed or
refractory non-Hodgkin lymphomas [35].
This study has some limitations. First, the retrospect-
ive nature of the study design was prone to selection
bias. Patients in this study tended to have a more aggres-
sive breast cancer with poorer prognosis in comparison
with a group from the general breast cancer patient
population, since all of those recruited were diagnosed
with MBC. Second, this study could not consider the
effects of adjuvant therapy, which differed according to
each patient, owing to the fact that patients were
recruited over a long period, from 1977 to 2013. Previ-
ous reports have demonstrated that examining change
due to treatment based on Ki-67 expression, the number
of responders to endocrine therapy as the neoadjuvant
therapy declined, and the prognosis of patients exhibit-
ing decreased levels of Ki-67 was good [36]. In addition,
the prognosis of patients with decreased levels after
chemotherapy was also reported to be good [37, 38].
Third, the EZH2 scoring method in this study was used
in house as described in the Materials and Methods
section. Forth, we could not assess EZH2 expression in
this study according to subtype (luminal A, luminal B,
luminal HER2, HER2-type and triple-negative breast
cancer) due to sample limitation. We assessed the clini-
copathological significance of EZH2 expression in MBC
according to subtype; however, the number of breast
cancer patients for each subtype was too small to show
statistical significance. Increasing the number of MBC
patients in this study was not possible since we had
already collected samples from 96 patients between 1977
and 2013, which was the maximum that was achievable.
Fifth, we used a HER2 immunostaining score of 2+ to
designate a negative score, as described in the Materials
and Methods section and Additional file 1.
As further investigations, we think that examination of
the correlation between EZH2 expression levels and
pathological response, and the correlation between EZH2
expression levels and prognosis in neoadjuvant chemo-
therapy and hormonal therapy should be considered.
Conclusion
Our results suggest that EZH2 expression levels correlate
significantly with the Ki-67 expression score. Therefore,
EZH2 may represent a potential therapeutic target for this
aggressive breast cancer, especially for those with a high
Ki-67 expression score, which warrants further investiga-
tion. EZH2 expression scores were significantly higher in
metastatic lesions compared with PBC lesions. We also
showed that high EZH2 expression levels in primary
lesions were independently associated with poorer DFS
and OS after primary surgery, and that high EZH2 expres-
sion levels in metastatic lesions were independently
associated with poorer OS outcomes after primary surgery
and recurrence. A part of the present work was preced-
ingly reported at the 2016 ASCO Annual Meeting [39].
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